Correlation between tumour characteristics, SUV measurements, metabolic tumour volume, TLG and textural features assessed with 18F-FDG PET in a large cohort of oestrogen receptor-positive breast cancer patients
- 944 Downloads
The study was designed to evaluate 1) the relationship between PET image textural features (TFs) and SUVs, metabolic tumour volume (MTV), total lesion glycolysis (TLG) and tumour characteristics in a large prospective and homogenous cohort of oestrogen receptor-positive (ER+) breast cancer (BC) patients, and 2) the capability of those parameters to predict response to neoadjuvant chemotherapy (NAC).
171 consecutive patients with large or locally advanced ER+ BC without distant metastases underwent an 18F-FDG PET examination before NAC. The primary tumour was delineated with an adaptive threshold segmentation method. Parameters of volume, intensity and texture (entropy, homogeneity, contrast and energy) were measured and compared with tumour characteristics determined on pre-treatment breast biopsy (Wilcoxon rank-sum test). The correlation between PET-derived parameters was determined using Spearman’s coefficient. The relationship between PET features and pathological findings was determined using the Wilcoxon rank-sum test.
Spearman’s coefficients between SUVmax and TFs were 0.43, 0.24, -0.43 and -0.15 respectively for entropy, homogeneity, energy and contrast; they were higher between MTV and TFs: 0.99, 0.86, -0.99 and -0.87. All TFs showed a significant association with the histological type (IDC vs. ILC; 0.02 < P < 0.03) but didn’t with immunohistochemical characteristics. SUVmax and TLG predicted the pathological response (P = 0.0021 and P = 0.02 respectively); TFs didn’t (P: 0.27, 0.19, 0.94, 0.19 respectively for entropy, homogeneity, energy and contrast).
The correlation of TFs was poor with SUV parameters and high with MTV. TFs showed a significant association with the histological type. Finally, while SUVmax and TLG were able to predict response to NAC, TFs failed.
KeywordsBreast cancer Oestrogen receptor-positive tumour 18F-FDG PET Texture features Metabolic tumour volume Total lesion glycolysis
Compliance with ethical standards
This study was in part supported by an academic grant (“Translational research in oncology” INCa-DHOS-5697).
Conflicts of interest
All the authors declared no conflicts of interest.
Research involving human participants and/or animals
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the principles of the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
For this ancillary study, written consent was not required.
- 2.NCCN. Clinical Pratice Guidelines on Oncology - Breast Cancer. 2015.Google Scholar
- 4.Groheux D, Hindié E, Delord M, Giacchetti S, Hamy A, Bazelaire C De, et al. Prognostic Impact of 18 FDG-PET-CT Findings in Clinical Stage III and IIB Breast Cancer. J. Natl. Cancer Inst. 2012;1879–87.Google Scholar
- 5.Groheux D, Cochet A, Humbert O, Alberini J-L, Hindié E, Mankoff D. 18F-FDG PET/CT for Staging and Restaging of Breast Cancer. J. Nucl. Med. Off. Publ. Soc. Nucl. Med. 2016;57 Suppl 1:17S–26S.Google Scholar
- 6.Humbert O, Berriolo-Riedinger A, Cochet A, Gauthier M, Charon-Barra C, Guiu S, et al. Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer. Eur J Nucl Med Mol Imaging. 2014;41:416–27.CrossRefPubMedGoogle Scholar
- 8.Groheux D, Sanna A, Majdoub M, Cremoux P de, Giacchetti S, Teixeira L, et al. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer. J. Nucl. Med. 2015;56.Google Scholar
- 10.Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, et al. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy. Cancer. 2013;119:1960–8.CrossRefPubMedGoogle Scholar
- 12.Tixier F, Cheze Le Rest C, Hatt M, Albarghach N, Pradier O, Metges J-P, et al. Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer. J Nucl Med. 2011;52:369–78.CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Groheux D, Majdoub M, Tixier F, Le Rest CC, Martineau A, Merlet P, et al. Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer? Eur J Nucl Med Mol Imaging. 2015;42:1682–91.CrossRefPubMedPubMedCentralGoogle Scholar
- 19.Hatt M, Tixier F, Pierce L, Kinahan PE, Le Rest CC, Visvikis D. Characterization of PET/CT images using texture analysis: the past, the present… any future? Eur. J. Nucl. Med. Mol. Imaging. 2016;1–15.Google Scholar
- 20.Bundschuh R a, Dinges J, Neumann L, Seyfried M, Zsótér N, Papp L, et al. Textural Parameters of Tumor Heterogeneity in 18F-FDG PET/CT for Therapy Response Assessment and Prognosis in Patients with Locally Advanced Rectal Cancer. J. Nucl. Med. 2014;55:891–7.Google Scholar
- 21.Orlhac F, Soussan M, Maisonobe J-A, Garcia CA, Vanderlinden B, Buvat I. Tumor texture analysis in 18F-FDG PET: relationships between texture parameters, histogram indices, standardized uptake values, metabolic volumes, and total lesion glycolysis. J Nucl Med. 2014;55:414–22.CrossRefPubMedGoogle Scholar
- 22.Hatt M, Majdoub M, Vallières M, Tixier F, Le Rest CC, Groheux D, et al. 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med. 2015;56:38–44.CrossRefPubMedGoogle Scholar
- 26.Kurani AS, Xu D, Furst J, Raicu DS. Co-occurrence matrices for volumetric data. 7th IASTED Int. Conf. Comput. Graph. Imaging, Kauai. 2004.Google Scholar
- 34.Orlhac F, Thézé B, Soussan M, Boisgard R, Buvat I. Multi-scale texture analysis: from 18F-FDG PET images to pathological slides. J. Nucl. Med. 2016Google Scholar
- 36.Dunnwald LK, Gralow JR, Ellis GK, Livingston RB, Linden HM, Specht JM, et al. Tumor metabolism and blood flow changes by positron emission tomography: relation to survival in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:4449–57.CrossRefGoogle Scholar